Author

Samith Thomas Kochuparambil

Observed names: S T Kochuparambil, S. T. Kochuparambil, S. Thomas Kochuparambil, S.T. Kochuparambil, Samith Kochuparambil, Samith T Kochuparambil, Samith T. Kochuparambil, T. Kochuparambil, Thomas Samith Kochuparambil

Institution: Minnesota Oncology

Observed institutions: Allina Health, Mayo Clinic, University of Georgia, Augusta University, Charlie Norwood VA Medical Center, Augusta University Health, Minnesota Oncology

ORCID: 0009-0003-2189-7304

Observed ORCID: 0009-0003-2189-7304

OpenAlex ID: A5043633072

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

2022 · Thomas Powles, Piotr Tomczak, et al. · The Lancet Oncology · 295

PDF

Phase 1/2a, open‐label, multicenter study of RM ‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

2021 · David M. Cognetti, Jennifer M. Johnson, et al. · Head & Neck · 186

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

2024 · Robert J. Motzer, Camillo Porta, et al. · Journal of Clinical Oncology · 181

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

2019 · Raffit Hassan, Anish Thomas, et al. · JAMA Oncology · 151

PDF

Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression

2010 · Samith T. Kochuparambil, Belal Al-Husein, et al. · Journal of Pharmacology and Experimental Therapeutics · 134

Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis

2012 · Anna Goc, Samith T Kochuparambil, et al. · BMC Cancer · 81

PDF

Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies

2012 · Mehdi Hamadani, S. Thomas Kochuparambil, et al. · Transplantation and Cellular Therapy · 73

PDF

Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA 2 mutations

2015 · Muhammad A. Mir, Samith T. Kochuparambil, et al. · Cancer Medicine · 50

PDF

Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies

2013 · F Awan, S T Kochuparambil, et al. · Bone Marrow Transplantation · 50

Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)

2020 · Benjamin L. Musher, Joshua E. Melson, et al. · Cancer Epidemiology Biomarkers & Prevention · 34

Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).

2019 · David M. Cognetti, Jennifer Maria Johnson, et al. · Journal of Clinical Oncology · 27

Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

2023 · Padmanee Sharma, Michael Krainer, et al. · Journal of Clinical Oncology · 26

RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial.

2018 · Ann M. Gillenwater, David Cognetti, et al. · Journal of Clinical Oncology · 25

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization

2012 · Farrukh T. Awan, S. Thomas Kochuparambil, et al. · Journal of Oncology · 14

PDF

Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.

2018 · Raffit Hassan, Anish Thomas, et al. · Journal of Clinical Oncology · 9

A Phase 2a, Multicenter, Open-Label Study of RM-1929 Photoimmunotherapy in Patients With Recurrent Head And Neck Cancer

2018 · D. Cognetti, J.M. Curry, et al. · International Journal of Radiation Oncology*Biology*Physics · 9

PDF

Novel Antibody Therapy in Acute Lymphoblastic Leukemia

2014 · Samith T. Kochuparambil, Mark R. Litzow · Current Hematologic Malignancy Reports · 9

A phase 1, multicenter, open-label, dose-escalation, combination study of RM-1929 and photoimmunotherapy in patients with recurrent head and neck cancer

2017 · S.T. Kochuparambil, D. McDonald, et al. · Annals of Oncology · 8

PDF

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer

2025 · Ming Lei, Michael J. Overman, et al. · Nature Communications · 7

PDF

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

2022 · Daniel J George, David R Spigel, et al. · BMJ Open · 6

PDF

Sarcoidosis Presenting with Pancytopenia

2014 · Shilpa Paul, Vinay Gupta, et al. · The American Journal of Medicine · 6

PDF

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

2011 · F T Awan, S Osman, et al. · Bone Marrow Transplantation · 5

Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)

2019 · J.M. Johnson, D.M. Cognetti, et al. · Annals of Oncology · 4

PDF

Quality of Life and Outcomes in Multiple Myeloma Patients

2014 · Shilpa Paul, Samith T. Kochuparambil, et al. · Blood · 4

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

2026 · Padmanee Sharma, Michael Krainer, et al. · Nature Communications · 3

Works count: 49

Citation count: 1,405

H-index: 14

I10-index: 14